View original post here:
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh